<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999295</url>
  </required_header>
  <id_info>
    <org_study_id>NCCH-1611</org_study_id>
    <nct_id>NCT02999295</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer</brief_title>
  <official_title>A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fiverings Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Japan</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and efficacy of the combination
      therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable
      gastric or GEJ cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Phase 1, course 1 (up to 28 days)</time_frame>
    <description>Number of participants with dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival rate after 6 months</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>Progression free survival rate after 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>from baseline to date of treatment cessation, approximately 24 months</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>from baseline to date of disease progression, approximately 24 months</time_frame>
    <description>percentage of participants with with a best response of complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>from baseline to date of disease progression, approximately 24 months</time_frame>
    <description>percentage of participants with with a best response of CR, PR or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from baseline to date of death, approximately 24 months</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>from baseline to date of disease progression or death, approximately 24 months</time_frame>
    <description>Progression free survival (PFS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Region (GEJ) Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Ramucirumab (8 mg/kg) is administered.</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>ONO-4538</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or recurrent unresectable gastric or GEJ cancer

          -  Histologically confirmed adenocarcinoma (papillary adenocarcinoma, tubular
             adenocarcinoma or poorly differentiated adenocarcinoma), signet-ring cell carcinoma,
             mucinous adenocarcinoma or hepatoid adnocarcinoma

          -  Patients with normal oral intake

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Patients who have measurable target lesion

          -  Patients has a refractory or intolerant pretreatment by pyrimidine fluoride anticancer
             agent and platinum-based anticancer agent

          -  Patients with adequate organ function

          -  Patients with no pretreatment history including ramucirumab, nivolumab or other
             therapies targeting control of T cells

          -  Patients with written informed consent

        Exclusion Criteria:

          -  Patients have double cancer

          -  Patients have infection required systemic therapy

          -  Known central vervous system (CNS) metastasis

          -  Patients with history of pneumonitis or pulmonary fibrosis

          -  Patients with history of serious anaphylaxis induced by antibody preparation

          -  Patients who have known active autoimmune disease or history of chronic recurrent
             autoimmune disease

          -  Female who is pregnant, lactating or suspected pregnancy

          -  Patients with psychosis or dementia to interfere to obtain informed consent
             appropriately
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kato, M.D. / Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastrointestinal Medical Oncology, National cancer center hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hirokazu Shoji</last_name>
    <phone>+81-3-3542-3815</phone>
    <email>hshouji@ncc.go.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatsushi Goto</last_name>
    <phone>+81-6-6358-7004</phone>
    <email>gotou@fiverings.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Kato, M.D./Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Japan</investigator_affiliation>
    <investigator_full_name>Ken Kato</investigator_full_name>
    <investigator_title>Head Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

